The European Medicines Agency’s advisory group CHMP has adopted a positive opinion backing the use of Eli Lilly’s (NYSE:LLY) Olumiant (baricitinib) for the treatment of moderate-to-severe atopic dermatitis in adults.

Olumiant is currently approved in Europe for moderate-to-severe rheumatoid arthritis.

A final decision from the European Commission usually takes ~60 days.


Source link

Comments to: European advisory group backs expanded use of Lilly’s Olumiant (NYSE:LLY)

Your email address will not be published. Required fields are marked *

Attach images - Only PNG, JPG, JPEG and GIF are supported.


Welcome to Typer

Brief and amiable onboarding is the first thing a new user sees in the theme.
Join Typer
Registration is closed.